Microbial and parasitic deoxyribonucleic acid (DNA)

Microbial and parasitic deoxyribonucleic acid (DNA) serves as the critical molecular target for nitroimidazole antibiotics in anaerobic or hypoxic environments. In these specific conditions, the drug acts as a prodrug that is selectively reduced by microbial enzymes, such as pyruvate:ferredoxin oxidoreductase, which are absent or less active in aerobic cells (NIH, 2022). This reduction generates highly reactive radical intermediates that interact with the DNA, causing covalent adduct formation and physical strand breakage. Consequently, the pathogen's ability to replicate and transcribe its genetic material is terminally disrupted, leading to cell death. This mechanism provides a high degree of therapeutic index, as the activation process is largely restricted to the low-oxygen environments characteristic of certain infections. It is the primary target for treating diseases like giardiasis, trichomoniasis, and infections caused by Bacteroides species (StatPearls, 2023). The selectivity of this target is further enhanced by the fact that human cells lack the high-affinity electron transport systems required to activate the drug under normal physiological conditions. Resistance to drugs hitting this target often involves mutations in the enzymes responsible for drug activation or increased oxygen-scavenging capabilities within the microbe.

Other names

Bacterial DNAProtozoal DNAGenomic DNAMicrobial DNAParasitic DNA

Reductive activation of nitroimidazole prodrugs by microbial electron transport proteins in anaerobic/hypoxic conditions leads to the formation of reactive radical intermediates that cause covalent binding to and fragmentation of microbial DNA, inhibiting synthesis and causing cell death (StatPearls, 2023; PubChem, CID 4173).